Showing 1971-1980 of 9355 results for "".
- Health Canada Approves BMS' Yervoy for Melanomahttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for_melanoma/2459869/Health Canada approved Yervoy (ipilimumab 3mg/kg, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced diseas
- Global Study Maps Wide Disparities in Access to Dermatologic Carehttps://practicaldermatology.com/news/global-study-maps-wide-disparities-in-access-to-dermatologic-care/2488213/A global analysis of dermatologic care found substantial disparities in dermatologist availability, training opportunities, and access to specialty services, with lower-resource countries facing the greatest gaps. The cross-sectional study surveyed dermatology leaders across World Health O
- AI Beauty Tools May Favor Narrower Facial Aesthetic Standards: Supplementhttps://practicaldermatology.com/news/ai-beauty-tools-may-favor-narrower-facial-aesthetic-standards-supplement/2488121/Artificial intelligence (AI) is emerging as another influence on facial aesthetic standards, potentially affecting how patients perceive attractiveness and approach cosmetic procedures, according to brief review in The Journal of Craniofacial Surgery. The authors explored how AI s
- Upadacitinib Meets Primary Endpoint in Two Phase 3 Alopecia Areata Trialshttps://practicaldermatology.com/news/upadacitinib-meets-primary-endpoint-in-two-phase-3-alopecia-areata-trials/2488081/New data suggests upadacitinib was associated with significantly greater scalp hair regrowth than placebo among adults and adolescents with severe alopecia areata (AA), according to findings published online August 12 in JAMA Dermatology. The replicate UP-AA1 and UP-AA2 trials enr
- Study: One-Third of Pemphigus Cases Deviate From Classic Desmoglein Compensation Modelhttps://practicaldermatology.com/news/study-one-third-of-pemphigus-cases-deviate-from-classic-desmoglein-compensation-model/2487700/
- CANDIN Meets Primary Endpoint in Phase 3 Common Wart Trialhttps://practicaldermatology.com/news/candin-meets-primary-endpoint-in-phase-3-common-wart-trial/2487261/Nielsen BioSciences announced positive topline findings from its Phase 3 trial evaluating CANDIN (Purified
- Randomized Trial Evaluates Educational Delivery Methods for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/randomized-trial-evaluates-educational-delivery-methods-for-pediatric-atopic-dermatitis/2487170/A randomized controlled trial published online in Pediatric Dermatology found that video-based therapeutic patient education (TPE) did not significantly outperform standard educational handouts for pediatric atopic dermatiti
- Topical NAC Plus Doxycycline Shows Benefit in Moderate Acnehttps://practicaldermatology.com/news/topical-nac-plus-doxycycline-shows-benefit-in-moderate-acne/2486948/Topical N-acetylcysteine (NAC) plus doxycycline was associated with greater improvement than benzoyl peroxide (BPO) plus doxycycline in patients
- Study: No Meaningful Link Between AD and Adolescent Academic Performancehttps://practicaldermatology.com/news/study-no-meaningful-link-between-ad-and-adolescent-academic-performance/2486567/Atopic dermatitis (AD) was not found to impair academic performance in adolscent patients, according to results from a new analysis of two large European cohorts. Researchers looked at two large, population-based cohort studi
- IMMpactful: Risankizumab Outperforms Deucravacitinib in Moderate Psoriasis at 16 Weekshttps://practicaldermatology.com/news/immpactful-risankizumab-outperforms-deucravacitinib-in-moderate-psoriasis-at-16-weeks/2486443/Risankizumab achieved higher rates of PASI 90 and PASI 100 compared with deucravacitinib at 16 weeks, alongside greater improvements in patient-reported symptoms and quality of life, new results from the IMMpactful trial suggested.